Skip Navigation LinksHome > September 2014 - Volume 26 - Issue 5 > Antibody drug conjugates
Current Opinion in Oncology:
doi: 10.1097/CCO.0000000000000108
LYMPHOMA: Edited by Bertrand Coiffier and Anne-Sophie Michallet

Antibody drug conjugates

Teicher, Beverly A.

Collapse Box

Abstract

Purpose of review

Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The more than 30-year history of antibody conjugates is marked by hurdles that have been identified and overcome.

Recent findings

Technology is continuing to evolve the protein and small molecule components, and it is likely that soon single-chemical entities will be the norm for antibody drug conjugates. More than 20 antibody conjugates are currently in clinical trials.

Summary

The time has arrived for this technology to become a major contributor to improving treatment for cancer patients.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.